Whole-process management of complications during CAR-T therapy

Author:

Li Yingying12,Mei Heng12

Affiliation:

1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2. Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy has substantial efficacy in the treatment of relapsed and/or refractory hematological malignancies. However, despite this outstanding performance, various CAR-T complications challenge treatment success during the entire process of CAR-T therapy. Short-term (within 28 days) complications with a high incidence include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and CAR-T associated coagulopathy. Many other complications may also occur during mid- (28–100 days) and long-term (>100 days) follow-up. Determining how to identify and standardize the management of adverse events in CAR-T therapy in an accurately and timely manner is crucial for its wide application. This review focuses on time periods after CAR-T cell therapy, and discusses the occurrence and management of adverse events, with an aim to improve the safety management of CAR-T cell therapy.

Publisher

Compuscript, Ltd.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3